Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H23NO4 |
| Molecular Weight | 317.3795 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1
InChI
InChIKey=VHSBBVZJABQOSG-INIZCTEOSA-N
InChI=1S/C18H23NO4/c1-22-17-8-3-13(11-18(17)23-2)9-10-19-12-16(21)14-4-6-15(20)7-5-14/h3-8,11,16,19-21H,9-10,12H2,1-2H3/t16-/m0/s1
| Molecular Formula | C18H23NO4 |
| Molecular Weight | 317.3795 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://medical.mt-pharma.co.jp/di/file/dc/kal.pdf
Sources: https://medical.mt-pharma.co.jp/di/file/dc/kal.pdf
Denopamine is a selective agonist of beta-1 adrenergic receptor. The drug was approved in Japan under the name Kalgut for the treatment of chronic heart failure.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P08588 Gene ID: 153.0 Gene Symbol: ADRB1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12487507 |
7.73 null [pEC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | KALGUT Approved UseChronic heart failure. Launch Date1988 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
19.2 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
15.5 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
16.9 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
12.3 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
14.2 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
11.6 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
7.8 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
10.7 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
10.7 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
22.4 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
68.3 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
57.2 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
59.3 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
43.6 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
80.8 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
72.2 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
55.6 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
65.3 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
65.3 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
137 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.02 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3.67 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3.6 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5.4 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4.5 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4.5 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4.8 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DENOPAMINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
57% |
DENOPAMINE plasma | Homo sapiens |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists. | 1999-11 |
|
| Cellular characterization of the pharmacological selectivity and tachyphylactic properties of denopamine for the human beta adrenergic receptors. | 1993-11 |
|
| Beta 1-adrenergic selectivity of the new cardiotonic agent denopamine in its stimulating effects on adenylate cyclase. | 1987-06-15 |
|
| Cardiovascular effects of the new positive inotropic agent denopamine with special reference to species difference and the effect on failing heart. | 1986-07 |
|
| Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. | 1986-04 |
|
| Metabolic fate of the new cardiotonic denopamine in animals. 2nd communication: tissue accumulation in the rat after consecutive oral administration of 14C-denopamine. | 1986-04 |
|
| In vitro metabolism of the new cardiotonic agent denopamine (TA-064) by rat and rabbit liver preparations. Oxidation, methylation, and glucuronidation. | 1985-03-01 |
|
| Relationship between positive inotropic action and blood levels of denopamine in cats. | 1985 |
|
| Cardiovascular effects of a new positive inotropic agent, (-)-(R)-1-(p-hydroxyphenyl)-2-[(3,4-dimethoxyphenethyl)amino]-ethanol (TA-064) in the anesthetized dog and isolated guinea pig heart. | 1984-08 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://medical.mt-pharma.co.jp/di/file/dc/kal.pdf
15-30 mg are administered orally in three divided doses.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://link.springer.com/article/10.1007/BF00168434
The effects of denopamine on the L-type Ca2+ current (ICa) were examined in rabbit ventricular cells. Denopamine stimulated basal ICa with a maximum response of +33.2% and a concentration for half-maximal response (EC50) of 0.039 uM. The maximun response of ICa was only a quarter of that induced by isoprenaline (ISO), while 10 uM denopamine elicited 70–75% of the maximum inotropic response in the papillary muscle preparations.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:18:00 GMT 2025
by
admin
on
Mon Mar 31 18:18:00 GMT 2025
|
| Record UNII |
V5F60UPD8P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5460
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
71771-90-9
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
C77934
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
C037293
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
Denopamine
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
CHEMBL493682
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
806
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
100000083180
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
SUB06977MIG
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
m4166
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | Merck Index | ||
|
V5F60UPD8P
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
DTXSID8045800
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY | |||
|
5311064
Created by
admin on Mon Mar 31 18:18:00 GMT 2025 , Edited by admin on Mon Mar 31 18:18:00 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
METABOLIC ENZYME -> SUBSTRATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |